Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Eur Addict Res. 2017;23(5):219-230. doi: 10.1159/000481348. Epub 2017 Sep 22.
Abstinence from alcohol has been the prevailing treatment goal for individuals with alcohol dependence (AD) within the context of specialty alcohol treatment. Yet, alcohol use has been conceptualized as existing on a continuum. Importantly, most people who meet criteria for AD and could benefit from treatment never receive treatment. About half of these individuals do not seek treatment because they report a desire to continue drinking. To increase acceptability of treatment, reductions in alcohol consumption have been examined as alternative outcomes in treatment trials for AD. The current study reviews data which indicate that long-term reduction in alcohol consumption among patients with AD is possible. Controlled studies have tested reduced alcohol consumption and show sustained improvements in drinking reductions for many patients following behavioral treatments and pharmacotherapy. Evidence-based treatment guidelines and medicines development guidance authorities have taken note of these developments and accept "intermediate harm reduction" (European Medicines Agency) or "low-risk drinking limits" (US Federal Drug Administration) as optional trial endpoints. In conclusion, while abstinence remains the safest treatment goal for individuals with AD, evidence supports that reduced drinking approaches may be an important extension in the treatment of AD.
在专业的酒精治疗环境中,戒酒一直是酒精依赖(AD)患者的主要治疗目标。然而,人们已经将酒精使用概念化为连续体。重要的是,大多数符合 AD 标准并可以从治疗中受益的人从未接受过治疗。这些人中约有一半人不寻求治疗,因为他们表示希望继续饮酒。为了提高治疗的可接受性,减少酒精摄入量已被作为 AD 治疗试验中的替代结果进行了研究。本研究回顾了数据,这些数据表明 AD 患者长期减少酒精摄入量是可能的。对照研究已经测试了减少酒精摄入量,并显示在行为治疗和药物治疗后,许多患者的饮酒量持续减少。循证治疗指南和药品开发指导当局已经注意到这些发展,并接受“中度减少伤害”(欧洲药品管理局)或“低风险饮酒限制”(美国联邦药物管理局)作为可选的试验终点。总之,虽然戒酒仍然是 AD 患者最安全的治疗目标,但有证据表明,减少饮酒的方法可能是 AD 治疗的重要延伸。